Hydra Lands Potential $195M Deal With Pfizer On Pain Drugs July 27, 2007 By Jim Shrine Hydra Biosciences Inc. licensed rights to its TRPV3 antagonist program to Pfizer Inc. in a deal valued at up to $195 million. (BioWorld Today)Read More
Washington roundup: QUEST, newest P4P program, will gauge results in 5 areas July 27, 2007 By Mark McCarty
RSS